Related Experiment Video
Updated: Apr 24, 2026

Measurement of Heart Contractility in Isolated Adult Human Primary Cardiomyocytes
Published on: August 9, 2022
[Pharmacogenetic aspects of antiarrhythmic drug therapy]
Abstract:
It is known for a long time that individuals vary widely in their responses to therapy with different drugs. Variability in drug response may be due to variability in the relationship between drug dose and concentrations of the drug at target sites (pharmacokinetic variability). Another mechanism is that individuals vary in their response to identical exposures to a drug due to variability in the target molecule with which a drug interacts or in biological microenvironment in which the "drug-target" interaction occurs (pharmacodynamic variability). Variants (polymorphisms and mutations) of genes that encode proteins important for pharmacokinetics or for pharmacodynamics are described as important contributors to variable drug actions. In this article pharmacogenetic and pharmacogenomic aspects of antiarrhythmic drug therapy and genetic factors contributing to proarrhythmia are reviewed.
More Related Videos
10:05Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug Toxicity: Risk factors
Pharmacogenetics of Drug Metabolism: Overview
Pharmacogenetics and Pharmacogenomics: Overview
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Drug toxicity: Idiosyncratic Reactions